What is it about?
This editoral comments on a previous original paper by Viglino et al. Thes Authors had found that nonalcoholic fatty liver disease is highly prevalent in chronic obstructive pulmonary disease (COPD) and might contribute to cardiometabolic comorbidities.
Featured Image
Why is it important?
Pneumologists should be aware of possible liver comorbidities in their COPD patients and hepatologists that the spectrum of extrahepatic disease in NAFLD may be wider than previously appreciated. Thus, for both groups of clinicians, the time has come to cross the diaphragm.
Perspectives
I hope this Editorial will prompt increased awareness that the human body consists of highly inter-correlated organs. A strictly specialistic (organo-centric) view will fail to appreciate the complexity of diseases.
Professor Amedeo LONARDO
Azienda Ospedaliero Universitaria di Modena - Ospedale Civile di Baggiovara - Modena, Italy
Read the Original
This page is a summary of: Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm?, European Respiratory Journal, June 2017, European Respiratory Society (ERS),
DOI: 10.1183/13993003.00546-2017.
You can read the full text:
Contributors
The following have contributed to this page
